TOP TEN perturbations for 1553131_a_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1553131_a_at
Selected probe(set): 205517_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1553131_a_at (205517_at) across 6672 perturbations tested by GENEVESTIGATOR:

expO ovary cancer study 1 (serous surface papillary carcinoma; metastatic) / expO ovary cancer study 1 (granulosa cell tumor, malignant; metastatic)

Relative Expression (log2-ratio):-5.351679
Number of Samples:2 / 2
Experimental expO ovary cancer study 1 (serous surface papillary carcinoma; metastatic)
Metastatic tumor tissue samples obtained from patients with primary serous surface papillary carcinoma of the ovary.
Control expO ovary cancer study 1 (granulosa cell tumor, malignant; metastatic)
Metastatic tumor tissue samples obtained from patients with primary granulosa cell tumor of the ovary.

expO ovary cancer study 1 (serous cystadenocarcinoma, NOS; metastatic) / expO ovary cancer study 1 (granulosa cell tumor, malignant; metastatic)

Relative Expression (log2-ratio):-5.174021
Number of Samples:8 / 2
Experimental expO ovary cancer study 1 (serous cystadenocarcinoma, NOS; metastatic)
Metastatic tumor tissue samples obtained from patients with primary serous cystadenocarcinoma (NOS) of the ovary.
Control expO ovary cancer study 1 (granulosa cell tumor, malignant; metastatic)
Metastatic tumor tissue samples obtained from patients with primary granulosa cell tumor of the ovary.

expO ovary cancer study 1 (papillary serous cystadenocarcinoma; metastatic) / expO ovary cancer study 1 (granulosa cell tumor, malignant; metastatic)

Relative Expression (log2-ratio):-5.1238747
Number of Samples:51 / 2
Experimental expO ovary cancer study 1 (papillary serous cystadenocarcinoma; metastatic)
Metastatic tumor tissue samples obtained from patients with primary papillary serous cystadenocarcinoma of the ovary.
Control expO ovary cancer study 1 (granulosa cell tumor, malignant; metastatic)
Metastatic tumor tissue samples obtained from patients with primary granulosa cell tumor of the ovary.

expO ovary cancer study 1 (granulosa cell tumor, malignant; metastatic) / expO ovary cancer study 1 (adenocarcinoma, NOS; metastatic)

Relative Expression (log2-ratio):5.069703
Number of Samples:2 / 7
Experimental expO ovary cancer study 1 (granulosa cell tumor, malignant; metastatic)
Metastatic tumor tissue samples obtained from patients with primary granulosa cell tumor of the ovary.
Control expO ovary cancer study 1 (adenocarcinoma, NOS; metastatic)
Metastatic tumor tissue samples obtained from patients with primary adenocarcinoma (NOS) of the ovary.

expO ovary cancer study 1 (granulosa cell tumor, malignant; metastatic) / expO ovary cancer study 1 (clear cell adenocarcinoma, NOS; metastatic)

Relative Expression (log2-ratio):5.06411
Number of Samples:2 / 4
Experimental expO ovary cancer study 1 (granulosa cell tumor, malignant; metastatic)
Metastatic tumor tissue samples obtained from patients with primary granulosa cell tumor of the ovary.
Control expO ovary cancer study 1 (clear cell adenocarcinoma, NOS; metastatic)
Metastatic tumor tissue samples obtained from patients with primary clear cell adenocarcinoma (NOS) of the ovary.

expO ovary cancer study 1 (granulosa cell tumor, malignant; metastatic) / expO ovary cancer study 1 (dysgerminoma; metastatic)

Relative Expression (log2-ratio):4.8081865
Number of Samples:2 / 2
Experimental expO ovary cancer study 1 (granulosa cell tumor, malignant; metastatic)
Metastatic tumor tissue samples obtained from patients with primary granulosa cell tumor of the ovary.
Control expO ovary cancer study 1 (dysgerminoma; metastatic)
Metastatic tumor tissue samples obtained from patients with primary dysgerminoma of the ovary.

expO ovary cancer study 1 (granulosa cell tumor, malignant; metastatic) / expO ovary cancer study 1 (carcinoma, NOS; metastatic)

Relative Expression (log2-ratio):4.7752924
Number of Samples:2 / 5
Experimental expO ovary cancer study 1 (granulosa cell tumor, malignant; metastatic)
Metastatic tumor tissue samples obtained from patients with primary granulosa cell tumor of the ovary.
Control expO ovary cancer study 1 (carcinoma, NOS; metastatic)
Metastatic tumor tissue samples obtained from patients with primary carcinoma (NOS) of the ovary.

expO ovary cancer study 1 (granulosa cell tumor, malignant; metastatic) / expO ovary cancer study 1 (endometrioid carcinoma; metastatic)

Relative Expression (log2-ratio):4.5044603
Number of Samples:2 / 3
Experimental expO ovary cancer study 1 (granulosa cell tumor, malignant; metastatic)
Metastatic tumor tissue samples obtained from patients with primary granulosa cell tumor of the ovary.
Control expO ovary cancer study 1 (endometrioid carcinoma; metastatic)
Metastatic tumor tissue samples obtained from patients with primary endometrioid carcinoma of the ovary.

expO ovary cancer study 1 (mucinous adenocarcinoma; metastatic) / expO ovary cancer study 1 (granulosa cell tumor, malignant; metastatic)

Relative Expression (log2-ratio):-4.431878
Number of Samples:2 / 2
Experimental expO ovary cancer study 1 (mucinous adenocarcinoma; metastatic)
Metastatic tumor tissue samples obtained from patients with primary mucinous adenocarcinoma of the ovary.
Control expO ovary cancer study 1 (granulosa cell tumor, malignant; metastatic)
Metastatic tumor tissue samples obtained from patients with primary granulosa cell tumor of the ovary.

HCC study 20 (CDX; Hep-G2; ectopic) / HCC study 20 (PDX; ectopic)

Relative Expression (log2-ratio):-3.9966493
Number of Samples:3 / 11
Experimental HCC study 20 (CDX; Hep-G2; ectopic)
Tumor tissue biopsy samples from Hep-G2 cell line-derived xenograft (CDX) ectopically generated in SCID mice by injecting hepatocellular carcinoma cells subcutaneously. In order to establish ectopic models, cells were injected subcutaneously into the flank regions. The mice were euthanized after two weeks.
Control HCC study 20 (PDX; ectopic)
Tumor tissue biopsy samples from patient-derived xenograft (PDX) sample ectopically generated in SCID mice by injecting hepatocellular carcinoma cells subcutaneously. Donor tumor tissue was obtained intraoperatively during liver resection from three patients. All three patients had hepatocellular carcinoma confirmed by histology. In order to establish ectopic models, cells were injected subcutaneously into the flank regions. The mice were euthanized after two weeks.